A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma

Scarisbrick, J.; Child, Fiona; Clift, Ashley Kieran; Sabroe, R.A.; Whittaker, Sean; Spittle, Margaret F.; Russell‐Jones, Robin

doi:10.1046/j.1365-2133.2001.04191.x

Cited by 48 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…131 Scarisbrick and colleagues studied the efficacy of fludarabine plus cyclophosphamide in 12 patients with advanced CTCL; 8 patients had SS. 52 Five of 8 patients with SS responded, including 1 CR, but bone marrow toxicity was significant. The authors concluded that, although this protocol might offer clinical benefit, there did not appear to be any evidence of improved survival.…”

Section: Chemotherapy Many Different Chemotherapeuticmentioning

confidence: 96%

See 1 more Smart Citation

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

391

308

View full text Add to dashboard Cite

Section: Chemotherapy Many Different Chemotherapeuticmentioning

confidence: 96%

“…The authors concluded that, although this protocol might offer clinical benefit, there did not appear to be any evidence of improved survival. 52 12.6.2.3. Alemtuzumab.…”

Section: Chemotherapy Many Different Chemotherapeuticmentioning

confidence: 99%

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

391

308

View full text Add to dashboard Cite

“…It is difficult to compare the results of these studies, some of them being prospective and others retrospec- 29 Foss et al, 30 Scarisbrick et al, 31 Quaglino et al 32 39 Foss, 40 Ho et al, 41 Greiner et al, 42 Cassileth et al, 43 Tsimberidou et al 44 33 tive. Moreover, the methods of assessing response were not the same across studies, and the durations of response were not calculated in the same way.…”

Section: Commentmentioning

confidence: 99%

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

Quéreux

Marques²,

Nguyen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…• Several studies have demonstrated potential synergy between purine analogs and alkylating therapies. In one recent study, 12 patients with refractory CTCL received fludarabine and cyclophosphamide [31]. Nine patients had erythrodermic CTCL and three patients had tumor-stage MF.…”

Section: Conventional Chemotherapymentioning

confidence: 99%

Therapy for mycosis fungoides

Lundin

Österborg²

2004

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Treatment of mycosis fungoides (MF) is indicated to reduce symptoms, improve clinical appearance, prevent secondary complications, and prevent progression of disease, all of which may have an impact on survival. Treatment of MF includes topical and systemic therapies, which can be administered alone or in combination. Psoralen and ultraviolet A radiation is effective in early-stage MF, inducing complete remissions in most patients. Psoralen and ultraviolet A radiation may also be combined with low doses of interferon (IFN)-alpha to treat stage I/II disease. However, early aggressive therapy with radiation and chemotherapy does not improve the prognosis. Local radiotherapy or total skin electron beam irradiation has been used with success to control advanced skin disease. Extracorporeal photopheresis may also be used successfully, but it is not generally available. Once the disease becomes refractory to topical therapy, IFN-alpha single-agent or combination chemotherapy may be administered, but the duration of response is often less than 1 year and ultimately all patients will relapse and become refractory. Among chemotherapeutic agents, pentostatin, gemcitabine, and liposomal doxorubicin seem to be particularly effective. Response rates after combined modality therapy with total skin electron beam irradiation and chemotherapy/IFN-alpha appear similar to response rates of chemotherapy alone. Therefore, there is a great need for the further development of novel emerging treatment modalities, such as retinoids (ie, bexarotene) and immunotherapeutic agents (ie, cytokines, tumor vaccines, and monoclonal antibodies), all of which appear to have significant therapeutic potential in patients with MF. Biologically based therapies may reduce the need for genotoxic therapies, such as cytostatics and radiotherapy.

show abstract

A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma

Cited by 48 publications

References 23 publications

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

Therapy for mycosis fungoides

Contact Info

Product

Resources

About